Abstract: This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy, particularly nucleoside reverse transcriptase inhibitor therapy using phenotypic susceptibility assays or genotypic assays.

Abstract: This invention provides a process for the preparation of a racemic mixture of dysidiolide a method for inhibiting growth of cancerous cells comprising contracting an amount of the racemic mixture of dysidiolide effective to inhibit the growth of said cells. Further provided is a method for treating cancer in a subject which comprises administering to the subject a therapeutically effective amount of the racemic mixture of dysidiolide.

Abstract: An apparatus for displaying paper, fabric, photographs or the like, comprises a long, narrow strip of thin ferromagnetic spring steel, and a number of small tacks embedded with rare earth magnets or other magnets. A tape-like dispenser stores unused tacks and a portion of the strip that has yet to be used. The strip of spring steel is covered on one face by a strong adhesive. The adhesive side, when the strip has not been used, is covered by a protective layer, such as wax paper. The spring steel is rolled up inside the dispenser. The strip may be divided at regular intervals by a cut through the protective paper and adhesive layer, the cut line scoring the spring steel.

Abstract: This invention provides isolated nucleic acids encoding mammalian SNORF25 receptors, purified mammalian SNORF25 receptors, vectors comprising nucleic acid encoding mammalian SNORF25 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF25 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF25 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF25 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF25 receptors, methods of isolating mammalian SNORF25 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF25 receptors, as well as methods of determining binding of compounds to mammalian SNORF25 receptors, methods of identifying agonists and antagonists of SNORF25 receptors, and agonists and antagonists so identified.

Abstract: This invention provides isolated nucleic acid molecules encoding envelope-interacting protein-1 and envelope-interacting protein-3. This invention provides fusion proteins comprising EIP-1, EIP-3, or fragments thereof and a second peptide. This invention provides vectors comprising the isolated nucleic acid molecule, encoding mammalian EIP-1 and EIP-3. This invention provides plasmid designated pCGN-EIP-l and pCGN-EIP-3. This invention provides purified mammalian EIP-1 and EIP-3 proteins. This invention provides monoclonal or polyclonal antibodies directed to epitopes of an EIP-1 or an EIP-3. This invention provides a method of increasing transduction efficieny of a retrovirus on target cells comprising: a) incubating an envelope-interacting protein with a retrovirus; and b) transducing the target cells with the retrovirus.

Abstract: Novel pyridone mimetics are disclosed which are useful for the treatment of SH2 domain related diseases.

Abstract: The present invention provides for a method for inhibiting tumor invasion or metastasis in a subject which comprises administering to the subject a therapeutically effective amount of a form of soluble Receptor for Advanced Glycation Endproducts (RAGE). The present invention also provides a method for evaluating the ability of an agent to inhibit tumor invasion in a local cellular environment which comprises: (a) admixing with cell culture media an effective amount of the agent; (b) contacting a tumor cell in cell culture with the media from step (a); (c) determining the amount of spreading of the tumor cell culture, and (d) comparing the amount of spreading of the tumor cell culture determined in step (c) with the amount determined in the absence of the agent, thus evaluating the ability of the agent to inhibit tumor invasion in the local cellular environment.

Abstract: A reinforced structure of the front lower panel for a package air conditioner may comprise a front lower panel, which is mounted on the front lower portion of the indoor unit of the air conditioner having a blower device for air circulation, evaporator coils for heat exchange, permitting the air inside the interior space to flow into the indoor unit for passing across the evaporator coils through the air inlets 12 and 12′, and includes the reinforcement structures formed on the inner corner portion between a front frame 11a and a side portion of the frame 11c having air guides 20 of the front lower panel 11, to strengthen the structural rigidity of the frames.

Abstract: The present invention relates to a method for the preparation for camptothecin and camptothecin-like compounds and to novel intermediates used in this preparation. In particular, the invention provides a process for the preparation of the camptothecin derivative of formula (I′) known by the chemical name “7-(4-methylpiperazino-methylene)-10,11-ethylenedioxy-20(R,S)-camptothecin”, which comprises cyclising the compound of formula (II′), wherein X is halogen, particularly chloro, bromo, or iodo; and when the compound of formula (I′) is obtained as a mixture of enantiomers optionally resolving the mixture to obtain the desired enantiomer; and/or if desired, converting the resulting compound of formula (I′) or a salt thereof into a physiologically acceptable salt or solvate thereof.

Abstract: The present invention provides an indoor unit of a package air conditioner sustaining a high air cooling efficiency and improved exterior appearance by constituting the front lower panel of indoor unit with a plate and a frame and making the imbibed indoor air dispersed evenly over the entire heat exchanger through a first air inlet port provided between the plate and the frame and second air inlet ports on the side of the frame. The front lower panel 11 of the indoor unit 10 according to the present invention is consisted of a frame 11a installed on the front lower portion of the main body and of a plate 11b placed with an inclination of the predetermined angle for the frame 11a and has a first air inlet port 12 and second air inlet ports 12′ through which the indoor air is flown, wherein the first air inlet port 12 is formed between the plate 11b and the frame 11a and the second air inlet ports 12′ is formed on the side portion of the frame 11a.

Abstract: This invention is directed to compounds of the following formula: wherein when a is 0, b is 1 or 2; when a is 1, b is 1, m is from 0-3, X is 0 or S, Y is halogeno, R1 is hydrogen C1-4 alkyl, R2 is hydrogen, C1-4 alkyl, or optionally substituted propargyl and R1 and R4 are each independently hydrogen, C1-6 alkyl, C6-12 aryl, C6-12 aralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome. Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Abstract: A detectably labeled porphyrin compound for identifying a sentinel lymph node in patients, particularly those with cancer. A method of identifying a sentinel lymph node, comprising the steps of: injecting the detectably labeled porphyrin compound into a tumor, wherein the porphyrin compound is detectably labeled with a radiolabel which is a &ggr;-emitting radioactive metal; and detecting radioactive emission or a color so as to detect and thereby identify the sentinel lymph node. A method of identifying a sentinel lymph node, comprising the steps of injecting the detectably labeled porphyrin compound into tissue surrounding a tumor, wherein the porphyrin compound is detectably labeled with a non-radioactive metal; and taking a series of magnetic resonance images to identify the sentinel lymph node by viewing the images showing the injected detectably labeled porphyrin compound.

Abstract: A joint prosthesis for attachment to a bone of a patient, comprising an anchor with a head surface and a stem for attachment to an end of the bone, the head surface having an anatomically accurate shape.

Abstract: The invention relates to processes for inserting into eucaryotic cells a multiplicity of DNA molecules which includes genes coding for desired proteinaceous materials. The insertion of multiple copies of desired genes is accomplished by cotransformation with the desired genes and with amplifiable genes for a dominant selectable marker in the presence of successively higher amounts of an inhibitor. Alternatively, the insertion of multiple copies of desired genes is accomplished by transformation using DNA molecules formed by ligating a DNA molecule including the desired gene to a DNA molecule which includes an amplifiable gene coding for a dominant selectable phenotype such as a gene associated with resistance to a drug in the presence of successively higher amounts of an agent such as a drug against which the gene confers resistance so that only those eucaryotic cells into which multiple copies of the amplifiable gene have been inserted survive.

Abstract: This invention provides for an isolated protein specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916. This invention also provides for an isolated protein having substantially the same biological activity as the aforementioned isolated protein. In addition, this invention provides for a pharmaceutical composition comprising the isolated protein and a pharmaceutically acceptable carrier.

Abstract: This invention provides methods of: (a) diagnosing; (b) determining the stage of; and (c) monitoring the effect of a therapeutic intervention for a renal cell carcinoma in a human subject which comprises detecting the expression of the MN gene. In one embodiment, the method is directed to detection of the renal cell carcinoma known as clear cell carcinoma. In another embodiment, the method is used as a peripheral blood assay. In another embodiment, the method is a polymerase chain reaction assay for amplifying and detecting the presence of the cDNA molecule encoding the MN protein.

Abstract: This invention provides a method of inhibiting an allergic response in a subject by inhibiting T cell activation of B cells, wherein said method comprises administering to the subject an antibody capable of binding to a protein which is specifically recognized by monoclonal antibody 5C8 produced by the hybridoma having ATCC Accession No. HB 10916.

Abstract: The invention consists of a non-naturally occurring nucleic acid molecule capable of blocking or interfering with a replicative intermediate of a virus, a virusoid, or a viroid. The nucleic acid molecule may contain a ribozyme or a plurality of ribozymes. Alternatively, the nucleic acid molecule may be an antisense nucleic acid molecule. The ribozyme may be a hairpin ribozyme, a hammerhead ribozyme, an RNAase P ribozyme, a minizyme, or other catalytic RNA molecule. The virus may be an animal, a mammalian, a plant, a fungal, a protozoan, a yeast, a bacterial virus, or a human virus. The nucleic acid molecule may be expressed in the cell or it may be preformed and administered ex vivo. The present invention contemplates methods of controlling infection of a pathogenic infectious agent in a plant or animal.

Abstract: This invention provides an expression vector encoding a CD4-gamma2 chimeric heavy chain homodimer. This invention also provides an expression vector encoding the heavy chains of a CD4-IgG2 chimeric heterotetramer. Finally, this invention provides an expression vector encoding the light chains of a CD4-IgG2 chimeric heterotetramer.

Abstract: A handler system is provided with an on-loader unit for loading at least one of strips deposited in a cassette, a drawer unit for holding the strip from the on-loader unit at a drawer picker, a strip transferring unit for fixing in a suction manner after the holding its picker head and for transferring the strip to a cutting device, cut it into a plurality of individual package devices, a package cleaning unit for cleaning the individual package devices using a brush and an air nozzle after to fixing and retaining the individual package devices thereon by using a suction vacuum force, a package drying unit for drying the individual package devices after the cleaning, a package deposit unit for moving and depositing after drying, a package pick-up unit for retaining and for arranging the individual package devices for a quality inspection, the package pick-up unit mounted on one side of the package deposit unit, a visual inspection means for inspecting the quality of the individual package devices being, and a